Literature DB >> 1925092

Tissue plasminogen activator treatment of experimental subretinal hemorrhage.

M W Johnson1, K R Olsen, E Hernandez.   

Abstract

Previous investigators have suggested that subretinal blood damages the retina in part because of its solid fibrin meshwork. The role of fibrinolysis in facilitating the clearance of subretinal hemorrhage and preventing degeneration of the overlying retina was studied. Autologous whole blood (0.1 ml) was injected into the subretinal space of 20 rabbits. Twenty-four hours later, the animals were randomized to subretinal treatment with 2.5 micrograms of tissue plasminogen activator or a similar volume of physiologic saline. Mean subretinal hemorrhage thickness 3 days after treatment had decreased to 42% of pretreatment thickness in treated eyes and remained unchanged in control eyes (P less than 0.0005). By 7 days mean clot thickness was 9% in treated eyes and 60% in controls (P = 0.005). Light microscopy revealed severe progressive retinal degeneration in both groups. No histologic evidence of retinal toxicity was found in cat retina after subretinal injection of tissue plasminogen activator (50 micrograms/ml). Although treatment with tissue plasminogen activator accelerated the clearance of subretinal hemorrhage, it failed to prevent secondary retinal degeneration in this rabbit model.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1925092     DOI: 10.1097/00006982-199111020-00011

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  10 in total

1.  Management of submacular hemorrhage with intravitreal versus subretinal injection of recombinant tissue plasminogen activator.

Authors:  Jost Hillenkamp; Vladimir Surguch; Carsten Framme; Veit-Peter Gabel; Helmut G Sachs
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-08-11       Impact factor: 3.117

2.  Plasminogen in proliferative vitreoretinal disorders.

Authors:  P Esser; K Heimann; K U Bartz-Schmidt; P Walter; R Krott; M Weller
Journal:  Br J Ophthalmol       Date:  1997-07       Impact factor: 4.638

3.  Subretinal injection of recombinant tissue plasminogen activator for submacular hemorrhage associated with ruptured retinal arterial macroaneurysm.

Authors:  Makoto Inoue; Fumio Shiraga; Yukari Shirakata; Yuki Morizane; Shuhei Kimura; Akito Hirakata
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-11-25       Impact factor: 3.117

4.  Management of subretinal macular haemorrhage by direct administration of tissue plasminogen activator.

Authors:  R P Singh; C Patel; J E Sears
Journal:  Br J Ophthalmol       Date:  2006-04       Impact factor: 4.638

5.  Fibrinolysis of experimental subretinal haemorrhage without removal using tissue plasminogen activator.

Authors:  L S Morse; J D Benner; L M Hjelmeland; M B Landers
Journal:  Br J Ophthalmol       Date:  1996-07       Impact factor: 4.638

6.  Recombinant tissue plasminogen activator in the treatment of suprachoroidal hemorrhage.

Authors:  Nancy Kunjukunju; Christine R Gonzales; William S Rodden
Journal:  Clin Ophthalmol       Date:  2011-02-04

7.  Intravitreal Expansile Gas and Bevacizumab Injection for Submacular Hemorrhage Due to Neovascular Age-related Macular Degeneration.

Authors:  Ramin Nourinia; Mohammad Hossein Jabbarpour Bonyadi; Hamid Ahmadieh
Journal:  J Ophthalmic Vis Res       Date:  2010-07

Review 8.  [Management of submacular hemorrhage : What, when, how?]

Authors:  Lars-Olof Hattenbach; Salvatore Grisanti; Nicolas Feltgen; Argyrios Chronopoulos
Journal:  Ophthalmologe       Date:  2020-09       Impact factor: 1.059

9.  Pneumatic displacement with intravitreal bevacizumab for massive submacular hemorrhage due to polypoidal choroidal vasculopathy.

Authors:  Masayasu Kitahashi; Takayuki Baba; Madoka Sakurai; Hirotaka Yokouchi; Mariko Kubota-Taniai; Yoshinori Mitamura; Shuichi Yamamoto
Journal:  Clin Ophthalmol       Date:  2014-03-03

10.  Combined Administration of Preoperative Intravitreal and Intraoperative Subretinal Recombinant Tissue Plasminogen Activator in Acute Hemorrhagic Age-related Macular Degeneration.

Authors:  Khaled Helaiwa; Lina R Paez; Peter Szurman; Kai Januschowski
Journal:  Cureus       Date:  2020-03-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.